{"entity":{"id":"nct06434610","kind":"trial","name":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","aka":[],"tldr":"A phase 2 trial of Paclitaxel / nab-paclitaxel in ovarian cancer, run by Shanghai Jiaolian Drug Research and Development Co., Ltd, now recruiting.","summary":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT06434610 by Shanghai Jiaolian Drug Research and Development Co., Ltd, with 90 participants planned, started 2024-07-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: B013, Paclitaxel, Placebo. Conditions listed: Platinum-resistant Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06434610","url":"https://clinicaltrials.gov/study/NCT06434610"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06434610","phase":"2","setting":"A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","enrolled":90,"outcomes":[]},"route":"/trials/nct06434610/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}]}}